Sunrest Lifescience IPO

Sunrest Lifescience Limited

₹1,34,400 /1600 sharesMinimum Investment

Sunrest Lifescience IPO Listing Details

Listed OnIssue Price
NSE₹84.00

Sunrest Lifescience IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
7 Nov ‘23 - 9 Nov ‘23₹1,34,4001,600₹84 - ₹84
Issue SizeIPO Doc
10.85Cr
RHP PDF

About Sunrest Lifescience

Incorporated in 2017, Sunrest Lifescience operates in the domestic market, focusing on marketing OTC generic pharmaceutical products. They offer a variety of pharmaceutical products sourced from third-party manufacturers. The company has a presence in different states of India, including Maharashtra, Gujarat, Madhya Pradesh, Orissa, and Rajasthan. Their presence in these states is established through both trademark-registered products and products currently under registration. Sunrest Lifescience deals in various pharmaceutical products, including capsules, tablets, syrup, ointment, gel, mouthwash, solution, suspension, dry powders, and toothpaste. Their product portfolio encompasses a broad spectrum of drugs, such as anti-bacterial, anti-diarrheal, antifungal, anti-material, anti-diabetic, dental cure, anti-protozoal, anti-histamine, anti-hypertensive drugs, cosmetic, anti-parasitic, multivitamin, multimineral, nutraceutical, and anti-inflammatory medications. The company holds 18 registered trademarks for 32 different products. The company’s products are distributed to stockists and super stockists, and they, in turn, make these products available in chemist shops, dispensaries, hospitals, and other similar establishments. ;
Parent Organisation
Sunrest Lifescience Limited
Founded
2017
Managing Director
Mr. Nikhilkumar Y Thakkar

Strengths & Risks

  • Sunrest Lifescience holds 18 registered trademarks for 32 different products.
  • It specializes in a variety of healthcare products, including capsules, tablets, liquid ointments, gels, ice gels, mouthwashes, pastes, solutions, suspensions, dry powders, and toothpaste.
  • Their extensive product range encompasses various drug categories, such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, dental care, proton pump inhibitors, antiprotozoal, antihistamine, antihypertensive, antilipidemic drugs, antiparasitic, multivitamins, multimineral nutraceuticals, and non-steroidal anti-inflammatory drugs (NSAIDs).
  • Currently, Sunrest Lifescience operates in five states: Maharashtra, Gujarat, Madhya Pradesh, Orissa, and Rajasthan. They collaborate with third-party manufacturers in these locations, with a total of 43 third-party manufacturers across these states. They plan to extend their geographical reach soon.
  • Sunrest Lifescience is currently involved in various legal proceedings involving the company, its directors, and its promoter. The company is also entangled in tax-related matters, specifically with two pending cases in the Income Tax department.
  • Sunrest Lifescience heavily relies on third-party manufacturers for its production. This dependence exposes the company's business activities to fluctuations in the prices of raw materials.
  • In the past year, the company issued equity shares at a price lower than the original Issue Price.
  • As of June 30, 2023, Sunrest Lifescience has borrowed an unsecured loan of Rs. 3.23 crore, subject to repayment on demand. Any such demand from lenders may adversely impact the company's cash flow and financial condition.
  • Recent financial records reveal negative cash flow from the company's operating activities. Sustained negative cash flow could potentially harm the company's business, financial health, and operational results.
  • The company typically conducts business with its customers on a purchase-order basis, avoiding long-term contracts with most of them.
  • For product delivery, Sunrest Lifescience depends on third-party transportation services. Any disruptions in their operations or a decline in service quality could impact the company's reputation and operational results.
  • As of June 30, 2023, the company has non-funded contingent liabilities totaling Rs. 0.38 crore. These liabilities encompass claims against the company and equity commitments related to an existing investment.

Financials

*All values are in Rs. Cr
No Graph Data To Display

Application details

Apply asPrice bandApply upto
Regular84 - 84₹2 Lakh
High Networth Individual84 - 84₹2 - 5 Lakh
For Sunrest Lifescience IPO, eligible investors can apply as Regular.
ⓒ 2016-2023 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 4.5.1
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  GROWWMF |  SBI |  AXIS |  HDFC |  UTI |  NIPPON INDIA |  ICICI PRUDENTIAL |  TATA |  KOTAK MAHINDRA |  DSP |  CANARA ROBECO |  SUNDARAM |  MIRAE ASSET |  BANDHAN |  FRANKLIN TEMPLETON |  PPFAS |  MOTILAL OSWAL |  INVESCO |  EDELWEISS |  ADITYA BIRLA SUN LIFE |  LIC |  HSBC |  NAVI |  QUANTUM |  UNION |  IDBI |  ITI |  MAHINDRA MANULIFE |  360 ONE |  BOI |  TAURUS |  JM FINANCIAL |  PGIM |  SHRIRAM |  BARODA BNP PARIBAS |  QUANT |  WHITEOAK CAPITAL |  TRUST |  SAMCO |  NJ |  BAJAJ

ABOUT GROWW